ChondroFiller™ is available in Lincolnshire

ChondroFiller™ for hip cartilage is available locally in Lincolnshire — patients do not need to travel to London to access it. The treatment is delivered through Lincolnshire Hip, a private consultant-led clinic with two sites: Grantham and Sleaford. Professor Paul Lee leads the service at both locations, carrying out assessment, injection, and follow-up appointments without requiring a GP referral. Patients can self-refer directly into the pathway.

The injection itself is an ultrasound-guided outpatient procedure performed under local anaesthetic. There is no general anaesthetic, no theatre admission, and no overnight stay. On-site open MRI is available for patients who do not yet have recent hip imaging, so the full assessment can be completed locally too. The only element of the pathway that moves outside Lincolnshire is hip replacement surgery, should that ever become necessary — and even then, Professor Lee performs that at Weymouth Street Hospital in London, with transport arranged from the patient's door.

Whether ChondroFiller is right for your hip

Hip cartilage is avascular — it carries no blood supply and, once worn or torn, cannot repair itself through the normal healing cascade that mends other tissues. That biological limitation is what makes a scaffold-based approach clinically relevant.

ChondroFiller™ works through a process called acellular matrix-induced chondrogenesis: in plain terms, the injected collagen gel forms a temporary three-dimensional scaffold inside the joint that the body's own progenitor cells migrate into, mature within, and use to build fibrocartilage-like repair tissue. The scaffold itself biodegrades. The injection does not replace cartilage directly — it supports the hip joint's own repair processes where unaided repair is impossible.

Who is likely to benefit

Ideal candidates have MRI-confirmed focal hip cartilage damage and have tried conservative management — physiotherapy, anti-inflammatory medication, or earlier injections — without sufficient relief. No fixed defect-size threshold applies, making ChondroFiller suitable for diffuse wear patterns as well as discrete focal lesions, provided imaging shows the damage is short of end-stage loss.

Who is unlikely to benefit

Patients with advanced hip osteoarthritis — broadly Tönnis grade 2–3, where cartilage loss is extensive — tend to have poorer outcomes, and hip replacement is likely to serve them better. Active joint infection and complete cartilage loss are firm contraindications. ChondroFiller addresses structural repair rather than immediate pain relief, so patients should expect improvement to build progressively over months, not days.

How to access treatment without a GP referral

Once contact is made — by phone or online enquiry — the Lincolnshire Hip team arranges a consultation at Grantham or Sleaford. If imaging is already to hand, Professor Lee can review it ahead of or during that appointment. Where scans are absent or outdated, on-site open MRI means a current picture of the joint can be obtained without the patient travelling further.

What follows is the part that carries real clinical weight. Professor Lee maps the cartilage defect in detail — its location within the acetabulum or femoral head, its depth, and its extent — to assess whether the scaffold can be placed to cover the affected area under ultrasound guidance. That mapping exercise also determines how much product is required, which shapes the total cost.

The treatment decision — whether ChondroFiller is the right fit, whether an alternative injection better suits the presentation, or whether the degree of joint wear points toward hip replacement — is confirmed at that assessment stage. Patients leave with a definite plan, not a provisional one. Injection booking, pre-treatment instructions, and follow-up scheduling are all managed within the same pathway.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

What the injection appointment involves

On the day of the injection, patients attend one of two outpatient clinic rooms — Grantham or Sleaford — and go home the same afternoon.

The appointment itself is straightforward. Using real-time ultrasound imaging, Professor Lee guides the needle accurately into the hip joint and delivers the ChondroFiller gel directly to the damaged area under local anaesthetic. Once inside the joint, the liquid collagen self-gels within minutes, forming a stable three-dimensional scaffold in place. No theatre admission is involved.

The number of vials required depends on the size and pattern of the cartilage defect mapped during the prior assessment. A larger or more diffuse defect calls for more product, and total cost rises accordingly — at £2,995 per vial at Lincolnshire Hip, this is worth factoring in early.

The weeks that follow

After the injection a protected loading period of four to six weeks is recommended. During this time, activity is modified to allow the scaffold to integrate properly with the surrounding tissue; heavy impact and loaded sport should be avoided, though ordinary daily movement is generally maintained. This phase is not passive rest — it is the biological window in which the body's own progenitor cells begin migrating into the scaffold.

Recovery and the repair timeline

From roughly three to six months after injection, the biology becomes visible in outcomes data. MOCART imaging scores — a standardised MRI measure of defect filling and tissue integration — rise from around 65 at four weeks to 81.6 at one year, confirming that repair tissue is progressively maturing inside the joint rather than simply persisting unchanged. This is the window in which the patient's own progenitor cells, having migrated into the collagen matrix during the earlier loading phase, differentiate into chondrocyte-like cells and begin laying down fibrocartilage-like repair tissue.

The scaffold itself is temporary. Type I collagen biodegrades as the new tissue forms, and what remains is the body's own repair material occupying the defect — not a permanent foreign implant.

Functional improvement follows a similar gradual curve. Most patients notice meaningful change between three and six months; further gains continue as tissue matures. This trajectory is quite different from a corticosteroid injection, where symptomatic relief — if it comes — tends to arrive within days and is not accompanied by structural repair. ChondroFiller addresses the structural deficit rather than masking it, which is why the benefit builds slowly and why realistic expectations centre on months rather than weeks.

Follow-up assessment, including repeat MRI where clinically indicated, allows Professor Lee to track defect filling and plan any further management.

Cost, NHS funding, and the clinical evidence

ChondroFiller is self-funded private treatment at Lincolnshire Hip, priced at £2,995 per injection. NHS commissioning for this pathway is not currently established in England, and it is not covered as a standard benefit by most private medical insurance policies.

Some insurers — most commonly Bupa, Aviva, and WPA — have approved it on a case-by-case basis using CCSD codes W3111 and W8500. Approval is not guaranteed; written pre-authorisation must be obtained before treatment begins. Patients planning to claim should contact their insurer with the procedure codes and confirm cover in writing before booking.

What the evidence shows

The most directly relevant published study is a prospective cohort by Mazek et al. (2021), which followed 26 patients with femoroacetabular impingement (FAI) and acetabular cartilage lesions larger than 2 cm². At three to five years, 17 of 21 patients available for follow-up reported good or excellent outcomes. Patients with pre-existing Tönnis grade 2–3 osteoarthritis fared poorly — consistent with the suitability criteria applied at Lincolnshire Hip.

Across the broader ChondroFiller evidence base, pooled success rates run at 70–85% at three to five years. These figures span knee, hip, and small-joint applications; hip-specific data remain more limited than the knee evidence base, and that caveat is worth stating plainly. IKDC scores improve by approximately 30 points on average in published studies — comfortably above the minimal clinically important difference of 16.7 points. The reoperation rate of 3–8% compares favourably with microfracture, where rates of up to 41% have been reported in published series.